ArticleJornal de pediatria2026
Dynamic multimodal brain function monitoring enables quantitative severity grading and prognostic prediction in pediatric neurocritical care.
Article in Jornal de pediatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMultimodal Brain Function Monitoring (MBFM) enables simultaneous assessment of cerebral blood flow, intracranial pressure (ICP), and brain tissue oxygenation, providing dynamic evaluation for pediatric neurocritical care. This study evaluated MBFM-derived parameters, including perturbation factor (PF), edema factor (EF), ICP, and regional cerebral oxygen saturation (rSO₂), for disease severity stratification and prognostic prediction.
methodsWe prospectively enrolled 120 pediatric patients (6 months-12 years) in the PICU of the Children's Hospital, the Weifang People's Hospital (January 2022- November 2025). Continuous MBFM monitoring was performed for 72 h. Patients were stratified into mild, moderate, and severe groups using K-means and hierarchical clustering. Key predictive thresholds were identified via CART decision tree. Predictive performance for adverse outcomes, including Glasgow Outcome Scale scores, complications, and survival, was assessed by ROC analysis, logistic regression, Kaplan-Meier survival analysis, and decision curve analysis.
resultsPF, ICP, EF, and rSO₂ significantly differed among severity groups. PF predicted adverse outcomes with an AUC 0.86 (cutoff 0.34), while the combined model (PF + EF + ICP + rSO₂) improved the AUC to 0.91. Patients with PF > 0.34 and severe disease showed reduced 6-month survival (Log-rank χ² = 7.76, P = 0.005).
conclusionsMBFM provides a quantitative framework for grading pediatric neurocritical illness. PF is a core predictor, and integrating multimodal metrics enhances prognostic accuracy, guiding PICU interventions and outcome prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.